ESC 2017

Higher Intake of Carbohydrates May Increase Risk for Premature Death

Higher Intake of Carbohydrates May Increase Risk for Premature Death

An excess of carbohydrates may be to blame for higher risk of premature deaths, not fats.

Anacetrapib Reduces Major Coronary Events When Added to Intensive Statin Therapy

Anacetrapib Reduces Major Coronary Events When Added to Intensive Statin Therapy

Lower incidence of major coronary events for patients with atherosclerotic vascular disease receiving intensive statins is linked with use of anacetrapib.

Cardiovascular Event Risk Better Predicted by ApoB vs LDL Cholesterol Level

Cardiovascular Event Risk Better Predicted by ApoB vs LDL Cholesterol Level

Clinical benefit of reduced low-density lipoprotein cholesterol (LDL-C) levels may depend on the corresponding reduction in apolipoprotein B (apoB)-containing lipoprotein particles.

Incidence of Undiagnosed AF Identified by Insertable Cardiac Monitors High

Incidence of Undiagnosed AF Identified by Insertable Cardiac Monitors High

Incidence for undiagnosed atrial fibrillation high from insertable cardiac monitors.

Comparison of PCI Outcomes With Bivalirudin vs Heparin Post-STEMI or NSTEMI

Comparison of PCI Outcomes With Bivalirudin vs Heparin Post-STEMI or NSTEMI

By

In patients undergoing percutaneous coronary intervention for either STEMI or NSTEMI, bivalirudin and heparin produce similar outcomes.

Suspected MI: No Difference Between Supplemental Oxygen and Ambient Air Treatment

Suspected MI: No Difference Between Supplemental Oxygen and Ambient Air Treatment

By

Supplemental oxygen therapy does not decrease the risk for 1-year all-cause mortality in patients with suspected myocardial infarction.

Greater CV Benefit With Rivaroxaban Plus Aspirin vs Monotherapy in Stable ASCVD

Greater CV Benefit With Rivaroxaban Plus Aspirin vs Monotherapy in Stable ASCVD

By

Despite more major bleeding events, rivaroxaban plus aspirin therapy had a greater cardiovascular benefit in patients with stable atherosclerotic vascular disease vs monotherapy.

Atherosclerotic Disease Benefits From Interleukin-1β Targeting

Atherosclerotic Disease Benefits From Interleukin-1β Targeting

By

In high-risk patients with atherosclerotic disease, canakinumab may help reduce the incidence of cardiovascular events.

Sign Up for Free e-Newsletters